Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Provided By GlobeNewswire
Last update: Jun 9, 2025
Placebo-subtracted mean weight loss up to 8.4% at Day 36
19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination
Well-tolerated with no safety signals
NASDAQ:MTSR (6/17/2025, 10:33:06 AM)
26.095
-0.78 (-2.88%)
Find more stocks in the Stock Screener
MTSR Latest News and Analysis
8 days ago - ChartmillLet's uncover which stocks are experiencing notable gaps during today's session.Let's have a look at the gap up and gap down stocks in today's session.
8 days ago - ChartmillGet insights into the top gainers and losers of Monday's pre-market session.The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
